Diana Rofail MSc

Welcome to the website of Diana Rofail B.Sc. (Hons) M.Sc.

October 17th, 2006 by

Diana Rofail

Zithromax Dosage Price For Nizoral Get High Amoxil Review Herbal Elavil High Doses Where To Get Nexium Spain Elavil Dosage Herbal Aricept Cheapest Pills Buying Inderal Aldactone Dosing Lasix Female Viagra Forum Price For Prevacid Health Forum Erythromycin Dosage Taking Stromectol Price For Doxycycline Swaziland Where To Get Cymbalta Shipping Where Order Tramadol Italy Cytotec Shop Female Viagra Tablets Herbal Ultram Overnight Delivery Phentrimine Generic Cymbalta OklahomaCity Where Order Lipitor Get High Price For Nizoral Tablets Discount Hoodia Drug Information Celexa Dosage Where To Get Antabuse Swaziland Prednisone Dosage Generic Nexium Testimonials Hoodia Faq Discount Stromectol For Add Buy Lotrisone Hartford Price For Celexa Dosing Soma Zelnorm NoRX Price For Diflucan Dosing Where Order Topamax Drug Information Price For Levitra Faq Order Lipitor OklahomaCity Where To Get Elimite Tablets Discount Clomid Online Clinic Neurontin Order Tramadol JeffersonCity Price For Seroquel Online Clinic Acomplia Where Order Inderal RX Discount Flomax Canada Amoxil Delivery Purchase Propecia OklahomaCity Lotrisone Shipping

Brunel University, London, UK

My interests include standard operational definitions of concepts, and the reliable and valid quantification of concepts via questionnaire development and psychometric validation. I am also particularly interested in phase II & III clinical trials and the use of Patient-Reported Outcomes (PROs) including patient satisfaction; adherence; symptom and side effects assessments; tolerability; & Health-Related Quality of Life (HRQoL).

I have occupational experience in the following areas: schizophrenia; bipolar disorder; parkinson’s disease; alzheimer’s disease; HIV/AIDS; oncology (breast cancer, ovarian cancer, cervical cancer, prostate cancer, non-small cell and small cell lung cancer); HPV; iron overload (thalassemia/sickle cell disease/myelodysplastic syndromes); asthma/COPD; & chronic low back pain (CLBP).

Treatments include: atypical and typical antipsychotic medications; protease inhibotors & non-nucleoside reverse transcriptase inhibitors; opioid analgesics; and infusion & oral iron chelation therapy.

I am also conducting a PhD in ‘Patient satisfaction and dissatisfaction with treatment for chronic low back pain’. This has involved in-depth patient and clinician interviews to identify important and relevant concepts and their inter-relationships. Based on this information questions were generated to develop a treatment satisfaction questionnaire. This is currently being psychometrically tested and results will be available soon.

For more information, please contact me on diana.rofail@swamscale.co.uk

Recent Publications

Rofail, D. Abetz, L. Viala, M. Gait, C. Baladi, JF. (In press) Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Pateint Instrument. Value in Health.

Payne, KA. Desrosiers, MP. Caro, J. Baladi, JF. Lordan,N. Proskorovsky,I. Ishak,K. Rofail, D. (2007). Clinical and Economic Burden of Infused Iron Chelation Therapy in the United States. Transfusion.

Capellini, MD. Bejaoui, M. Agaoglu, L. Porter, J. Coates, T. Jeng, M. Lai, M. Mangiagli, A. Strauss, G. Girot, M. Watman, N. Ferster, A. Logetto, S. Abish, S. Cario, H. Zoumbos, N. Vichinsky, E. Opitz, H. Ressayre-Djaffer, C. Abetz, L. Rofail, D. Baladi, JF. (2007). Prospective Evaluation of Patient-Reported Outcomes During Treatment with Deferasirox or Deferoxamine for Iron Overload in Patients with Beta-Thalassemia. Clinical Therapeutics.

Abetz, L. Baladi, J.B. Jones, P. Rofail, D. (2006). The Impact of Iron Overload and its Treatment on Quality of Life: Results From a Literature Review. Health and Quality of Life Outcomes.

Rofail, D. Gray, R. Gournay, K. (2005). The Development and Internal Consistency of the Satisfaction With Antipsychotic Medication (SWAM) scale. Psychological Medicine.

Gray R. Rofail, D. Allen, J. Newey, T. (2005). A Survey of Patient Satisfaction With, And Subjective Experiences of, Treatment with Antipsychotic Medication. Journal of Advanced Nursing.

Presentations

Rofail, D. Scott, J. Thompson, G. Dubois, D. Peeters, K. Development of the Tolerability Index for Patients with HIV Receiving Anti-Retroviral Therapy. (2007). Poster to be presented at the International Society of Quality of Life Research (ISOQOL).

Rofail, D. Viala,M. Abetz, L. Gait, C. Development and Scoring of the Satisfaction With Iron Chelation. (2006). Proceedings of the International Pharmacoeconomics and Outcomes Research (ISPOR).

Rofail, D. Viala,M. Baladi, J. Brunn, C. (2006). Satisfaction With ICT Predicts Never Thinking About Stopping Chelation Therapy in Patients With Iron Overload. Poster Presented in Istanbul Turkey, at the European Society for Medical Oncology.

Payne KA Desrosiers M-P, Proskorovsky I, Ishak K, Baladi J-F, and Rofail, D. (2006). Burden of Current Iron Chelation Therapy in Some United Kingdom Treatment Centres. Poster Presented in Istanbul Turkey, at the European Society for Medical Oncology.

Mantovani LG, Ravera S, Rofail D, Cappellini MDand the ITHACA Study Group. (2006). Health Related Quality of Life in Patients With Beta Thalassemia Major: The Ithaca Study. ISPOR.

Rofail, D. & Myers, L.B. (2006). Patient Satisfaction With Treatments in Chronic Low Back Pain (CLBP): A Systematic Review of the Literature. Poster presented in Essex UK, at The British Psychological Society Division of Health Psychology Conference.

Rofail, D. Allan, K. Dubois, D. Peeters, K. (2006). A Review of Patient Reported Outcomes Instruments in HIV/AIDS. Poster presented in Lisbon, at the International Society of Quality of Life (ISOQOL) Conference.

Rofail, D. Viala, M. Trudeau, E. Abetz, L. Baladi, JF. (2006). The Health Related Quality of Life in Patients Currently Treated for Iron Overload: Comparison of SF-36 and CHQ Scores to US and UK General Populations. Poster Presented in Amsterdam, at the European Haematological Association (EHA) Conference.

Rofail, D. Viala, M. Trudeau, E. Abetz, L. Baladi, JF. (2006). Factors Associated with Satisfaction in Patients with Thalassemia, Sickle Cell Disease, and Myelodysplastic Syndrome Taking Iron Chelation Therapy. Poser Presented in Amsterdam, at the European Haematological Association (EHA) Conference.

Rofail, D. Viala, M. Trudeau, E. Baladi, JF. (2006) Predictors of Adherence to Iron Chelation Therapy in Patients with Thalassemia, Sickle Cell Disease, and Myelodysplastic Syndromes. Poster Presented in Amsterdam, at the European Haematological Association (EHA) Conference.

Rofail,D. Abetz,L. Jenkins,D. Lindsay,L. DeVuyst,H. (2006). The Impact of HPV and Cervical Cancer on Health Related Quality of Life: A Review of Validated Instruments Currently Available. Proceedings of the International Pharmacoeconomics and Outcomes Research (ISPOR).

Abetz, L. Baladi, J.F. & Rofail, D. The potential Impact of Chelation Therapy (CT) on the Quality of Life (QoL) of Patients with Iron Overload (IO). (2005). Poster Presented in Florence, at the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Conference.

Abetz, L. Baladi, J.F. Jones, P. & Rofail, D. The Development of a Treatment Satisfaction Questionnaire for Iron Overload (IO) Patients on Chelation Therapy (CT). (2005). Poster Presented in Florence, at the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Conference.

Rofail, D. & Myers, L.B. Patient Satisfaction With Treatments in Chronic Low Back Pain (CLBP): A Systematic Review of the Literature. (2005). Poster Presented in Galway, at The European Health Psychology Society (EHPS) Conference.

Rofail, D. & Myers, L.B. The Development of a Satisfaction With Medication Scale. (2004). Proceedings of the British Psychological Society. Poster Presented in Edinburgh, The Division of Health Psychology (DHP) Annual Conference.

Rofail, D. Abetz, L. Lobosco, S. Murphy, K. & Hividsten, K. The Impact of Nocturnal Symptoms on Parkinson’s Disease Patients: A Review of the Literature. (2004). Poster Presented in Paris, at the European Federation of Neurological Societies (EFNS).

Satisfaction with antipsychotic medication is an important outcome variable. The development, dimensionality, reliability and validity of the Satisfaction with Antipsychotic Medication (SWAM) scale is described in Rofail et al. (2005).The SWAM scale has been culturally adapted and is now available in other languages. It reliably and validly quantifies patients satisfaction with psychiatric treatment based on an operational definition according to two factors: (1) Treatment Acceptability (positive orientations towards treatment); and (2) Medication Insight (self awareness, knowledge, and understanding in to the need for medication and its potential side effects).

The SWAM scale has been used in clinical practice and clinical drug trials. A user agreement must be signed before it is implemented in study (trial or survey), and this can be requested by emailing: info@swamscale.co.uk

Copyright of The SWAM Scale:

Please note that all translations, adaptations, and scoring algorithms, and any other related documents of the Satisfaction With Antipsychotic Medication (SWAM) Scale, including the Satisfaction With Antipsychotic Medication (SWAM) Scale, are owned and copyrighted by Diana Rofail, and the intellectual property of, Diana Rofail, MSc. Copyright protection is also extended to electronic versions of all SWAM documents and products.

No changes to the wording or phrasing of any SWAM document can occur without written permission. If any changes are made to the wording or phrasing of any SWAM item without permission, the document cannot be considered the SWAM scale, and subsequent analyses and/or comparisons to other SWAM data will not be considered appropriate.

Permission to use the name “SWAM” will not be granted for any unauthorized translations of the SWAM or SWAM items. Any analyses or publications of unauthorized changes or translated versions may not use the SWAM name. Any unauthorized translation will be considered a violation of copyright protection.

The SWAM copyright information provided on these documents must be included on every page of a SWAM questionnaire in study documents, and in any reproductions for manuscript or other publication purposes.

If there are issues of scientific or copyright misconduct in using the SWAM scale, Diana Rofail reserves the right to withdraw permission for use and seek damages to the full extent provided by international copyright law.

Please email info@swamscale.co.uk for more information.